The role of osteoprotegerin in arthritis
© BioMed Central Ltd 2003
Received: 1 July 2003
Accepted: 31 July 2003
Published: 8 August 2003
Bone erosion is a hallmark of rheumatoid arthritis. Recent evidence from experimental arthritis suggests that osteoclasts are essential for the formation of local bone erosions. Two essential regulators of osteoclastogenesis have recently been described: the receptor-activator of nuclear factor kappa B ligand, which promotes osteoclast maturation, and osteoprotegerin (OPG), which blocks osteoclastogenesis. The present review summarizes the current knowledge on the role of osteoclasts in local bone erosion. In addition, the role of OPG as a therapeutic tool to inhibit local bone erosion is addressed. Finally, evidence for OPG as an inhibitor of systemic inflammatory bone loss is discussed.
Keywordsbone erosion osteoclasts osteoporosis osteoprotegerin rheumatoid arthritis
Local bone erosions in rheumatoid arthritis
Rheumatoid arthritis (RA) is a highly osteodestructive process, which leads to local, juxta-articular and systemic bone loss. Local bone erosion is part of the classification criteria of RA, has become a key monitoring parameter of RA and is associated with unfavorable prognosis, such as functional loss [1–3].
From these histopathological observations it was evident that synovial inflammatory tissue has unique invasive properties, which even enable the invasion of bone and, finally, the destruction of bone. The molecular basis of this invasive nature has not been completely clarified and appears to be of a complex nature. Decreased apoptosis, activation of mitogenic signaling pathways and expression of enzymes that degrade the extracellular matrix, such as matrix metalloproteinases, play a part in this process [5–7]. Elegant studies have also linked such characteristics with synovial fibroblast-like cells of RA patients, which have intrinsic invasive properties and thus facilitate the spreading of inflammatory synovial tissue .
Evidence for a pivotal role of osteoclasts in local bone erosions
Bone erosion requires osteoclasts and, since the work of Bromley and Woolley, it has been known that inflammatory synovial tissue harbors osteoclasts . A detailed characterization of osteoclast precursors and mature osteoclasts within local bone erosions was then accomplished by Gravallese and colleagues in the late 1990s, demonstrating that cells in synovial pannus show all the different maturation steps of the osteoclast lineage . Furthermore, typical histological features of resorption lacunae were detected at the site of the erosion fronts. Lacunae are filled with multinucleated giant cells featuring typical morphological and molecular characteristics of mature osteoclasts.
Outcome of arthritis in osteoclast-free mouse models
Pettit et al. 
Redlich et al. 
K/BxN (serum transfer)
Mechanism of arthritis
Immune complex driven
Mechanism of bone pathology
Stromal cell defecta
Bone marrow cell defectb
Effect on inflammation
Effect on cartilage damage
Effect on bone erosion
Presence of osteoclasts
Further direct evidence for a pivotal role of osteoclasts in local bone erosion comes from c-fos knockout mice, which exhibit a maturation arrest of the osteoclast lineage without affecting differentiation of other hematopoetic cells or changing the properties of the stroma . These mice show complete uncoupling of synovial inflammation and bone erosion when arthritis is induced by overexpression of tumor necrosis factor (TNF) . The osteoclast thus emerges as an essential prerequisite to form erosive arthritis, and therefore appears an attractive therapeutic target for RA.
Concepts to inhibit osteoclasts in arthritis
Blockade of TNF-α and IL-1 are other currently used strategies. Both cytokines are potent osteoclastogenic factors, produced in inflammatory arthritis. Interestingly, clinical trials have shown that the effects of TNF-blockers on bone damage may exceed those effects on inflammation, suggesting that their ability to hamper osteoclast formation might be of important benefit [20, 21]. This is especially supported by the results from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy, which showed that the effect of TNF-blockers on bone damage is independent of a clinical response to treatment . Other current experimental approaches such as the application of RGD peptides, of proton pump inhibitors, of matrix metalloproteinase inhibitors and also of blockers of mitogen-activated protein kinases/stress-activated protein kinases may add a future therapeutic repertoire to block osteoclasts.
Osteoprotegerin as inhibitor of osteoclastogenesis
Osteoprotegerin (OPG) has emerged as one of the most attractive tools to inhibit osteoclast formation during the past years. The interaction of RANKL with its receptor-activator of nuclear factor kappa B (RANK) is an essential signal for osteoclastogenesis [22–24]. Mice deficient for RANKL or RANK are osteopetrotic due to complete lack of osteoclasts [24, 25]. Thus, the interaction of RANKL, which is expressed by stromal cells and activated T cells, with RANK, found on osteoclast precursor cells and mature osteoclasts, is essential for osteoclastogenesis and osteoclast activation.
OPG functions as a naturally occurring decoy receptor of RANK and inhibits the RANKL/RANK interaction [26, 27]. Evidence that OPG has profound effects on bone comes from OPG knockout mice, which are osteoporotic due to deregulated RANKL/RANK interaction and increased osteoclast formation , and also comes from the administration of OPG to laboratory animals and humans, which leads to an increase of bone mass [28, 29]. The rationale for using OPG to inhibit the formation of local bone erosions in patients with RA comes from several observations: the presence of osteoclasts in local bone erosions as described earlier [9, 10], the increased expression of RANKL and RANK within synovial inflammatory tissue [30–32], and the fact that many proinflammatory mediators present in the synovial membrane, such as TNF, IL-1, IL-17 and prostaglandin E2, induce RANKL expression [33–35].
The effects of OPG on local bone erosion
Effects of osteoprotegerin in animal models of arthritis
Kong et al. 
Redlich et al. 
Romas et al. 
Onset of symptoms
Onset of symptoms
Onset of symptoms
Effect on inflammation
Effect on cartilage damage
Effect on bone erosion
Effect on osteoclast count
Effect on osteoporosis
These data suggest that, regardless of the nature of the precipitating mechanism, OPG appears a powerful tool to inhibit bone damage following synovial inflammation. Moreover, the RANKL/RANK interaction appears an important step in the formation of synovial osteoclasts, which is further supported by similar effects of other strategies to suppress RANKL expression, such as adeno-viral-based overexpression of IL-4, which is a potent antagonist of RANKL .
Systemic inflammatory bone loss and OPG
Apart from local bone erosion, systemic bone loss is a serious health burden in patients with RA. Osteoporosis develops in the majority of RA patients and is associated with increased fracture risk [39, 40]. Several factors precipitate systemic bone loss in RA patients, including female gender, high age, systemic use of glucocorticoids and decreased mobility of RA patients due to functional impairment. Interestingly, however, disease activity is also a major predictor for osteoporosis in RA patients, and is independent of other precipitating factors . This suggests that the inflammatory process not only affects local bone, but also leads to bone loss at distant sites, possibly due to a disturbed cytokine balance with a negative net effect on bone.
Open questions on OPG in arthritis
Currently, no data on the effects of OPG in human RA are available. Given the results from animal models of RA, the major role of OPG in human RA might be protection from local bone erosion and systemic bone loss. Whether bone can be protected more efficiently by OPG than by other strategies, such as anti-TNF, anti-IL-1 or potent bisphosphonates, remains to be determined.
In the TNF-transgenic model, OPG was equally potent to TNF-blockade in blocking local bone erosions, and was superior to the IL-1 receptor antagonist (unpublished observations). Recent data suggest that OPG treatment might exert some inhibitory effect on synovial inflammation, especially if combined with a TNF-blocker (unpublished observations). This may be explained by blockade of RANKL/RANK interactions other than those involved in osteoclastogenesis, such as the interaction of T cells with dendritic cells . Furthermore, binding of OPG to surface molecules distinct from RANKL, which has been demonstrated for tumor-necrosis-factor-related apoptosis inducing ligand, for example , could affect synovial inflammation. Also, the influence of OPG on loss of articular cartilage is controversial. Whereas protection of articular cartilage by OPG has been described in the adjuvant arthritis model , it is weak in the collagen-induced arthritis model  and is completely absent in the TNF-transgenic model . Expression of RANKL and RANK by chondrocytes has been described, but the function of these molecules in the cartilage is unknown . Thus, it is as yet unclear whether OPG affects cartilage destruction and synovial inflammation to a relevant degree, whereas the effect on bone is unequivocally proven.
There is a bulk of evidence that osteoclasts have a central role in local and systemic bone loss of inflammatory arthritis. Furthermore, pharmacological doses of OPG inhibit the formation of local bone erosions and restore normal bone mass in experimental models of arthritis. OPG thus appears a promising agent to block bone loss in RA. Since there is only a weak effect, if any, of OPG on inflammation, it is probable that its potential use in RA patients needs to be flanked by sufficient anti-inflammatory treatment. Patients with a high risk of bone loss might profit substantially from OPG, and it will be a challenge to select such patients by current clinical, laboratory and radiological assessments.
receptor-activator of nuclear factor kappa B
receptor-activator of nuclear factor kappa B ligand
tumor necrosis factor.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger T, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilden RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.View ArticlePubMed
- Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K: The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000, 39: 122-132. 10.1093/rheumatology/39.2.122.View ArticlePubMed
- van der Heijde D, Dankert T, Nieman F, Rau R, Boers M: Reliability and sensitivity to change of a simplification of the Sharp/ van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford). 1999, 38: 941-947. 10.1093/rheumatology/38.10.941.View Article
- Weichselbaum A: Die feineren Veränderungen des Gelenkknorpels bei fungöser Synovitis und Karies der Gelenkenden. Archiv Pathol Anat Physiol Klin Med. 1878, 73: 461-475.View Article
- Sugiyama M, Tsukazaki T, Yonekura A, Matsuzaki S, Yamashita S, Iwasaki K: Localization of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis. 1996, 55: 442-449.PubMed CentralView ArticlePubMed
- Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G: Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2501-2512. 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K.View ArticlePubMed
- Pap T, Gay S, Schett G: Matrix metalloproteinases. In Targeted Therapies in Rheumatology. Edited by: Smolen JS, Lipsky P. 2003, London, New York: Martin Dunitz, 483-501.
- Pap T, Aupperle KR, Gay S, Firestein GS, Gay RE: Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum. 2001, 44: 676-681. 10.1002/1529-0131(200103)44:3<676::AID-ANR117>3.3.CO;2-Y.View ArticlePubMed
- Bromley M, Woolley DE: Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984, 27: 968-975.View ArticlePubMed
- Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998, 152: 943-951.PubMed CentralPubMed
- Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001, 159: 1689-1699.PubMed CentralView ArticlePubMed
- Kim N, Odgren PR, Kim DK, Marks SC, Choi Y: Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA. 2000, 97: 10905-10910. 10.1073/pnas.200294797.PubMed CentralView ArticlePubMed
- Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF: c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science. 1994, 266: 443-448.View ArticlePubMed
- Redlich K, Hayer S, Ricci R, David D, Tohidast-Akrad M, Kollias G, Günter Steiner S, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest. 2002, 110: 1419-1427. 10.1172/JCI200215582.PubMed CentralView ArticlePubMed
- Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B, Pietschmann P, Woloszczuk W, Kollias G, Steiner G, Smolen J, Schett G: Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002, 46: 785-792. 10.1002/art.10097.View ArticlePubMed
- Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, Konttinen YT: Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol. 2003, 30: 468-473.PubMed
- Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S: Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol. 2003, 30: 474-479.PubMed
- Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC: Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 1996, 39: 396-402.View ArticlePubMed
- Yilmaz I, Ozoran K, Gunduz OH, Ucan H, Yucel M: Alendronate in rheumatoid arthritis patients treated with methothrexate and glucocorticoids. Rheumatol Int. 2001, 20: 65-69. 10.1007/s002960000080.View ArticlePubMed
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.View ArticlePubMed
- Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000, 43: 1001-1009. 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P.View ArticlePubMed
- Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.View ArticlePubMed
- Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.PubMed CentralView ArticlePubMed
- Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999, 397: 315-323. 10.1038/16852.View ArticlePubMed
- Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J: RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13: 2412-2424. 10.1101/gad.13.18.2412.PubMed CentralView ArticlePubMed
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.View ArticlePubMed
- Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-1268.PubMed CentralView ArticlePubMed
- Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR: OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001, 142: 4295-4304. 10.1210/en.142.10.4295.PubMed
- Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001, 16: 348-360.View ArticlePubMed
- Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43: 250-258. 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P.View ArticlePubMed
- Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2523-2530. 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z.View ArticlePubMed
- Lubberts E, Oppers-Walgreen B, Pettit AR, van den Bersselaar L, Joosten LAB, Goldring SR, Gravallese EM, Van den Berg WB: Increase in expression of receptor activator of nuclear factor kB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum. 2002, 46: 3055-3065. 10.1002/art.10607.View ArticlePubMed
- Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.View ArticlePubMed
- Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. 2003, 170: 2655-2662.View ArticlePubMed
- Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000, 106: 1481-1488.PubMed CentralView ArticlePubMed
- Kong YY, Feige U, Saros I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprote-gerin ligand. Nature. 1999, 402: 304-309. 10.1038/46303.View ArticlePubMed
- Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT: Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol. 2002, 161: 1419-1427.PubMed CentralView ArticlePubMed
- Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 2000, 105: 1697-1710.PubMed CentralView ArticlePubMed
- Spector TD, Hall GM, McCloskey EV, Kanis JA: Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993, 306: 558.PubMed CentralView ArticlePubMed
- Gough AK, Lilley J, Eyre S, Holder RL, Emery P: Generalized bone loss in patients with early rheumatoid arthritis. Lancet. 1994, 344: 23-27. 10.1016/S0140-6736(94)91049-9.View ArticlePubMed
- Kvien TK, Haugeberg G, Uhlig T, Falch JA, Halse JI, Lems WF, Dijkmans BA, Woolf AD: Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000, 59: 805-811. 10.1136/ard.59.10.805.PubMed CentralView ArticlePubMed
- Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P: Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998, 25: 1282-1289.PubMed
- Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan CR, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen J: Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice. Arthritis Rheum. 2003,
- Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997, 390: 175-179. 10.1038/36593.View ArticlePubMed
- Shipman CM, Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003, 63: 912-916.PubMed
- Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M: The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001, 44: 2768-2776. 10.1002/1529-0131(200112)44:12<2768::AID-ART464>3.0.CO;2-I.View ArticlePubMed